The FDA notified consumers about Esbelta Intense Loss and Esbelta Chupapanza Flat Belly on 18 August. This is not substitution and it is not underdosing — it is undeclared pharmaceutical ingredients, which no amount of label arithmetic would have caught.
Reported on 12 August: three more online weight-loss products added to the FDA's yellow oleander alert, which now runs to 25. The failure here is not a dose problem — it is that the plant in the capsule was not the plant on the label.
A July launch release for a probiotic-and-botanical weight-management capsule puts 'Supplement Facts' in its own headline. It names three bacterial strains and nine other ingredients, and attaches a number to none of them.
A famous stimulant brand is back for Europe with a fully disclosed panel. The disclosure is genuinely good; the case published for three of the inclusions is not.
A May ruling held that a weight-loss supplement's own name would be read as a health claim the advertiser could not show was authorised — and that an injection-pen comparison table put it in the territory of prescription medicines.
A staple of fat-burner formulas, and the one ingredient here where the most important published finding is about harm rather than benefit.
Two words that can mean a rigorous trial or almost nothing at all. Here is what the phrase does not commit a brand to.
One of the few weight-management ingredients with a specific authorised health claim behind it in Europe — and a set of conditions most products quietly fail to meet.